2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow AZD5153: new trials by email Literature Review of AZD5153 trials Research Report on AZD5153
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas AZD5153, Olaparib - Malignant Solid Tumors, Lymphoma | Phase 1 | Completed | AstraZeneca | 49 | 2017-06-30 | 2021-05-06 |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | 3000 | 2016-11-01 | 2026-09-03 |
Breast Neoplasms (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Acerta Pharma BV (1) · AstraZeneca (1) · Beat AML, LLC (1)
United States (3) · Canada (1) · United Kingdom (1)
Alice Mims, MD (1) · Erika P Hamilton, MD (1) · Ian Flinn, MD, PhD (1)
2017 (1)